Odonate Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Odonate Therapeutics generated cash of $8,740,000, which is more than the previous year. Cash used in financing activities reached the amount of -$196,000 last year. Net change in cash is therefore $28,822,000.
Cash Flow
| 2015 | -165K | 0 | 0 |
|---|---|---|---|
| 2016 | -1.73M | 0 | 4.19M |
| 2017 | -25.85M | -83K | 221.44M |
| 2018 | -67.09M | -1.90M | 10.19M |
| 2019 | -96.63M | -166K | 138.67M |
| 2020 | -113.13M | -432K | 90.36M |
| 2021 | -75.72M | -26K | -12.75M |
| 2022 | 1.79M | -58.34M | -1.62M |
| 2023 | 8.74M | 20.15M | -196K |
ODTC Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 10.72M | 68.89M | 157.26M | 181.17M | 139.30M | 198.10M | 2.59M | 138K | 303K |
Operating activities | |||||||||
Net income | 7.32M | 42.94M | -68.31M | -126.35M | -111.82M | -88.96M | -32.74M | -3.08M | -158K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 21K | 342K | 1.05M | 445K | 381K | 350K | 20K | 0 | 0 |
Stock-based compensation expense | 0 | 0 | 0 | 9.82M | 11.44M | 6.72M | 3.18M | 51K | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 9.82M | 11.44M | 6.72M | 3.18M | 51K | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -22K | -270K | -13.87M | -1.41M | 4.78M | 6.39M | 3.64M | 529K | 4K |
Cash generated by operating activities | 8.74M | 1.79M | -75.72M | -113.13M | -96.63M | -67.09M | -25.85M | -1.73M | -165K |
Investing activities | |||||||||
Purchases Of Investments | -17.25M | -58.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | -26K | -432K | -166K | -1.90M | -83K | 0 | 0 |
Acquisitions Net | 0 | 54K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 20.15M | -58.34M | -26K | -432K | -166K | -1.90M | -83K | 0 | 0 |
Financing activities | |||||||||
Common Stock Issued | 0 | 0 | 825K | 87.38M | 135.09M | 9.84M | 221.44M | 5.01M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -791K | 0 |
Repurchases of common stock | 0 | -1.62M | -13.57M | 0 | 0 | 0 | 0 | -32K | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -791K | 0 |
Cash used in financing activities | -196K | -1.62M | -12.75M | 90.36M | 138.67M | 10.19M | 221.44M | 4.19M | 0 |
Net Change In Cash | 28.82M | -58.17M | -88.37M | -23.19M | 41.87M | -58.80M | 195.50M | 2.46M | -165K |
Cash at end of period | 39.54M | 10.72M | 68.89M | 157.97M | 181.17M | 139.30M | 198.10M | 2.59M | 138K |
| Data source | Data source | Data source | Data source |